SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending as investors remain divided over the companys aggressive capital framework and ongoing Bitcoin monetization strategy. While some community members are actively loading up on shares amid the price volatility, others are debating the sustainability of the company's debt-fueled business model and its reliance on institutional sentiment.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as investors anticipate a pivotal REGAL phase 3 readout and potential M&A activity, with community members actively discussing a short squeeze fueled by limited share availability. Long-term shareholders are doubling down, emphasizing the transformative potential of the GPS platform in oncology and sharing conviction in a significant valuation re-rate ahead of upcoming clinical milestones.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently in the spotlight following the announcement that NASA has selected the company to provide launch services for three Electron missions, fueling community speculation about a turnaround and potential short squeeze after recent share price volatility. While retail investors remain optimistic about the firm's long-term backlog and institutional inclusion in the Nasdaq-100, the stock continues to face pressure from sector-wide rotation following the recent SpaceX IPO.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors aggressively speculate on potential Russell 1000 inclusion, driving massive trading volume and a fierce battle between bullish sentiment and short sellers. The community remains hyper-focused on upcoming corporate catalysts, international expansion plans, and the potential for a gamma squeeze that could force short-covering ahead of the index rebalance.

Comcast Corp. engages in the provision of video, Internet, and phone services. It operates through the following segments: Residential Connectivity and Platforms, Business Services Connectivity, Media, Studios, and Theme Parks. The Residential Connectivity and Platforms segment consists of residential broadband and wireless services and Sky-branded entertainment television networks and advertising. The Business Service Connectivity segment offers broadband, wireline voice and wireless services through small to medium customers and large enterprises through the HFC network. The Media segment consists of NBCUniversal’s television and streaming platforms, including national, regional, and international cable networks. The Studios segment focuses on NBCUniversal’s film and television studio production and distribution operations. The Theme Parks segment operates Universal theme parks in Orlando, Florida, Hollywood, California, Osaka, Japan, and Beijing, China. The company was founded by Ralph Roberts in 1963 and is headquartered in Philadelphia, PA.

Comcast Corp - Ordinary Shares - Class A

Comcast Corp

Comcast is surging following the major announcement that it plans to spin off its NBCUniversal and Sky media and entertainment assets into a separate, publicly traded company. Investors are actively debating the long-term implications of this separation, with many focusing on the potential for enhanced value within the newly focused broadband-led entity versus the standalone media business.

Charter Communications, Inc. engages in providing broadband communications services. Its services include Spectrum TV, Spectrum Internet, and Spectrum Voice. It offers business-to-business Internet access, data networking, business telephone, video and music entertainment services, and wireless backhaul. Its advertising sales division, Spectrum Reach, offers local, regional, and national businesses the opportunity to advertise in individual and multiple service areas on cable television networks and advanced advertising platforms. The company was founded in 1993 and is headquartered in Stamford, CT.

Charter Communications Inc. - Ordinary Shares - Class A

Charter Communications is trending amid heightened community debate over its steep price decline and the potential for a disruptive partnership with SpaceX to provide mobile phone services via ground infrastructure. While some investors argue the stock is deeply undervalued due to aggressive buybacks and high cash flow, others are shorting the name, citing significant debt levels and declining subscriber numbers as the primary catalysts for the ongoing sell-off.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as investors digest its strategic expansion into AI-powered autonomous network infrastructure, highlighted by recent partnerships with major hyperscalers like Google Cloud and Amazon. While some in the community express frustration over recent price volatility and bearish technical patterns, many are highlighting significant insider buying and long-term positioning as a reason to view the current dip as an accumulation opportunity.

Iridium Communications, Inc. operates as a commercial provider of communications services offering true global coverage, connecting people, organizations and assets to and from anywhere, in real time. It offers its services to businesses, the U.S. and foreign governments, non-governmental organizations, and consumers via satellite network, which has an architecture of operational satellites with in-orbit spares and related ground infrastructure. Its products include personal communicators, messengers, and trackers, satellite phones, push-to-talk-devices, broadband terminals, midband terminals, external antennas, docking stations, apps, accessories and developer tools & resources. The company was founded in 2000 and is headquartered in McLean, VA.

Iridium Communications Inc

Iridium Communications is trending following a definitive agreement for Rocket Lab to acquire the company in a cash-and-stock deal valued at approximately $8 billion. The community is actively discussing the strategic synergy between Rocket Lab's launch capabilities and Iridium's satellite network, while some investors are debating the long-term implications of this consolidation in the broader space infrastructure sector.

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Viridian Therapeutics is trending following the FDA approval of Lumvoa, a treatment for thyroid eye disease, with the community closely tracking the company's immediate commercial launch plans and potential for market expansion. Investors are actively debating the stock's valuation, upcoming conference call details, and whether the approval will drive significant long-term growth or lead to profit-taking.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst is trending following the announcement that it will discontinue internal discovery programs and close its Alabama research facility to prioritize external innovation and improve cash flow. Community members are actively debating whether these cost-cutting measures are a disciplined strategic pivot toward sustainability or a sign that the company is cleaning up operations for a potential acquisition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RBC⬇️ $IDYA PT to $30 from $57, reiterated at OP and said &quot;Ph.III Readout in 2H25 Should Drive Upside and Unlock A $1B Revenue Oppt&#39;y; We are updating our views on $IDYA following additional diligence, KOL discussions, and meeting with mgmt&quot; 
$MRK $DSNKY $ZLAB $ONC PFE GILD 
RBC Capital added, &quot;While the stock has been largely range bound this year, with less investor attention, we believe as we enter the second half $IDYA should garner more attention given a major ph.Ill event for lead drug daro, as well as a number of supporting pipeline updates. 
 
We see a 65%+ likelihood of success for the ph.Ill readout in metastatic uveal melanoma coming towards year-end, and see 40% upside given potential for a rapid launch by 2026. 
 
With a lower risk and high reward catalyst, as well as pipeline clarity across &#39;897 and &#39;349, we would be buyers into 2H25; tgt to $30 and maintaining Outperform, Spec. Risk rating.&quot;

Wells Fargo🏁 $IDYA OW-$44~thinks the Street isn&#39;t pricing in enough value for daro&#39;s pot&#39;l in UM - &#39;25 updates should de-risk Tx in both first-line mUM &amp; the neo adjuvant setting - updates from early pipeline should offer upside in the next 12-18mo. 
$MRK $GILD PFE $DSNKY $XBI  
 
Wells Fargo said in its $IDYA initiation note: &quot;Shares are down -15% YTD vs $XBI -8% and believe the stock isn&#39;t pricing in daro&#39;s oppty at these levels. We like the setup over the next 12 mos, where the co plans to provide several data points for daro both in the metastatic and neoadjuvant settings that should get investors more confident on its potl in UM. 
 
Further, there is a good chance daro&#39;s pivotal mPFS readout is pos (65%), which could lead to an accelerated approval and launch in 2026 in 1L MUM.&quot;

StockTwits Web

Ideaya Biosciences Inc

Merck & Co Inc

Gilead Sciences, Inc.

Daiichi Sankyo Company

SPDR S&P Biotech ETF

Quantumup

TD Cowen🏁 $IDYA at a Buy rating. 
$PFE $GILD $DSNKY $AZN RHHBY 
 
TD Cowen in its initiation report said, &quot;IDEAYA&#39;s pipeline — with soon-to-be 9 clinical-stage programs — represents the best of targeted oncology and is led by a world-class team. 
 
The lead daro + criz combo should launch in 2026 in mUM, with a high likelihood of success in neoadjuvant. 
 
Near-term DLL3 ADC data are likely to be strong, and MAT2A efficacy should add to Trodelvy with NT data. We initiate at Buy given the very attractive EV.&quot;

Zai Lab Ltd

BeOne Medicines Ltd - ADR

 PT to $30 from $57, reiterated at OP and said "Ph.III Readout in 2H25 Should Drive Upside and Unlock A $1B Revenue Oppt'y; We are updating our views on 

 following additional diligence, KOL discussions, and meeting with mgmt" 


 PFE GILD 
RBC Capital added, "While the stock has been largely range bound this year, with less investor attention, we believe as we enter the second half 

 should garner more attention given a major ph.Ill event for lead drug daro, as well as a number of supporting pipeline updates. 
 
We see a 65%+ likelihood of success for the ph.Ill readout in metastatic uveal melanoma coming towards year-end, and see 40% upside given potential for a rapid launch by 2026. 
 
With a lower risk and high reward catalyst, as well as pipeline clarity across '897 and '349, we would be buyers into 2H25; tgt to $30 and maintaining Outperform, Spec. Risk rating."